Margaret A. Johnson

发表

Attenuated humoral responses in HIV after SARS-CoV-2 vaccination linked to B cell defects and altered immune profiles

R. Gilson, I. Williams, M. Youle, 2022, iScience.

Incomplete Reversibility of Estimated Glomerular Filtration Rate Decline Following Tenofovir Disoproxil Fumarate Exposure

C. Leen, D. Pillay, R. Gilson, 2014, The Journal of infectious diseases.

Simplification with abacavir-based triple nucleoside therapy versus continued protease inhibitor-based highly active antiretroviral therapy in HIV-1-infected patients with undetectable plasma HIV-1 RNA

B. Gazzard, J. Montaner, S. Staszewski, 2001, AIDS.

The SPICE Study: 48‐Week Activity of Combinations of Saquinavir Soft Gelatin and Nelfinavir With and Without Nucleoside Analogues

M. Opravil, N. Clumeck, A. Pozniak, 2000, Journal of acquired immune deficiency syndromes.

A highly virulent variant of HIV-1 circulating in the Netherlands

Michael J. Rausch, H. Jessen, A. Trkola, 2022, Science.

Durability of viral suppression with first-line antiretroviral therapy in patients with HIV in the UK: an observational cohort study

C. Leen, D. Pillay, R. Gilson, 2017, The lancet. HIV.

Survival after a very low (< 5 × 106/l) CD4+ T‐cell count in individuals infected with HIV

C. Sabin, A. Phillips, Christine A. Lee, 1997, AIDS.

Changes in CD4 lymphocyte counts after interruption of therapy in patients with viral failure on protease inhibitor-containing regimens

A. Phillips, M. Youle, C. Loveday, 2000, AIDS.

Immunological, virological and clinical response to highly active antiretroviral therapy treatment regimens in a complete clinic population

A. Phillips, M. Youle, C. Loveday, 2000, AIDS.

Attenuated humoral responses in HIV infection after SARS-CoV-2 vaccination are linked to global B cell defects and cellular immune profiles

R. Gilson, M. Youle, C. Pinder, 2022, bioRxiv.

Incoming HIV virion-derived Gag Spacer Peptide 2 (p1) is a target of effective CD8+ T cell antiviral responses.

C. Brander, V. Miller, T. Peto, 2021, Cell reports.

Use of a stochastic model to develop understanding of the impact of different patterns of antiretroviral drug use on resistance development

A N Phillips, A. Phillips, M. Youle, 2001, AIDS.

Immediate Versus Deferred Switching From a Boosted Protease Inhibitor–based Regimen to a Dolutegravir-based Regimen in Virologically Suppressed Patients With High Cardiovascular Risk or Age ≥50 Years: Final 96-Week Results of the NEAT022 Study

D. Podzamczer, B. Clotet, A. Winston, 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Hypersensitivity reactions, hepatotoxicity, and other discontinuations in persons receiving integrase strand transfer inhibitors: results from the EuroSIDA study

A. Mocroft, O. Kirk, D. Raben, 2021, HIV research & clinical practice.

A Mocroft, C. Sabin, M. Youle, 2001, HIV clinical trials.

Changes in multimorbidity burden over a 3–5 year period among people with HIV

A. Winston, C. Sabin, D. De Francesco, 2023, Frontiers in Systems Biology.

Virological outcomes of boosted protease inhibitor-based first-line ART in subjects harbouring thymidine analogue-associated mutations as the sole form of transmitted drug resistance

C. Leen, C. Fraser, E. Volz, 2018, The Journal of antimicrobial chemotherapy.

Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study

B. Gazzard, C. Katlama, K. Ruxrungtham, 2004, The Lancet.

Early virological response to HIV treatment: can we predict who is likely to experience subsequent treatment failure? Results from an observational cohort study, London, UK

A. Copas, A. Phillips, F. Lampe, 2017, Journal of the International AIDS Society.

Chronic Kidney Disease Risk in African and Caribbean Populations With HIV

B. Gazzard, C. Leen, D. Pillay, 2018, The Journal of infectious diseases.

Changes over time in risk of initial virological failure of combination antiretroviral therapy: a multicohort analysis, 1996 to 2002.

J. Gatell, A. Phillips, S. Staszewski, 2006, Archives of internal medicine.

Rapid decline in detectability of HIV-1 drug resistance mutations after stopping therapy.

M. Youle, C. Loveday, M A Johnson, 1999, AIDS.

Changing utilization of Stavudine (d4T) in HIV‐positive people in 2006–2013 in the EuroSIDA study

J. Nielsen, C. Leen, P. Vanhems, 2015, HIV medicine.

A Randomised Trial of Subcutaneous Intermittent Interleukin-2 without Antiretroviral Therapy in HIV-Infected Patients: The UK–Vanguard Study

R. Davey, H. Lane, M. Youle, 2006, PLoS clinical trials.

Safety of Tenofovir Alafenamide in People With HIV Who Experienced Proximal Renal Tubulopathy on Tenofovir Disoproxil Fumarate

A. Winston, L. Campbell, B. Barbini, 2021, Journal of acquired immune deficiency syndromes.

Abacavir-lamivudine-zidovudine vs indinavir-lamivudine-zidovudine in antiretroviral-naive HIV-infected adults: A randomized equivalence trial.

S. Hammer, J. Montaner, D. Cooper, 2001, JAMA.

Incoming HIV Virion-Derived Gag Spacer Peptide 2 (p1) is a Target of Effective CD8+ T Cell Antiviral Responses

C. Brander, V. Miller, T. Peto, 2020, SSRN Electronic Journal.

Early ribavirin improves sustained virological responses in acute HCV infection in HIV-positive individuals.

I. Williams, S. Bhagani, M. Danta, 2005 .

Reduced bone mineral density in HIV-positive individuals.

C. Sabin, A. Phillips, J. Studd, 2001, AIDS.

The Cost-Effectiveness of Early Access to HIV Services and Starting cART in the UK 1996 – 2008

R. Brettle, M. Youle, E. Beck, 2012 .

Changes in AIDS-defining illnesses in a London Clinic, 1987-1998.

A. Mocroft, C. Sabin, A. Phillips, 1999, Journal of acquired immune deficiency syndromes.

Continuation of emtricitabine/lamivudine within combination antiretroviral therapy following detection of the M184V/I HIV‐1 resistance mutation

Andrew L. Kerr, C. Leen, C. Fraser, 2020, HIV medicine.